Terms: = Breast cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
29606 results:
1. The use of longitudinal CT-based radiomics and clinicopathological features predicts the pathological complete response of metastasized axillary lymph nodes in breast cancer.
Wang J; Tian C; Zheng BJ; Zhang J; Jiao DC; Qu JR; Liu ZZ
BMC Cancer; 2024 May; 24(1):549. PubMed ID: 38693523
[TBL] [Abstract] [Full Text] [Related]
2. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center.
Deme D; Tamaskovics BF; Jammoul N; Kovács S; Kayode EO; Grice JW; Telekes A
Pathol Oncol Res; 2024; 30():1611735. PubMed ID: 38689824
[No Abstract] [Full Text] [Related]
3. Addressing Social Determinants in the Era of Precision Medicine in breast cancer: Is It Sufficient to Reduce Disparities?
Freeman JQ; Huo D
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):635-637. PubMed ID: 38689576
[TBL] [Abstract] [Full Text] [Related]
4. Evolution of neoadjuvant therapy for breast cancer regimens over 12 years and pathologic response rates according to tumor subtypes and clinical stage: A single-center retrospective study.
Li Z; Wang Y
J Cancer Res Ther; 2024 Apr; 20(2):608-614. PubMed ID: 38687931
[TBL] [Abstract] [Full Text] [Related]
5. Neoadjuvant Chemotherapy in Patients with her2-Negative breast cancer: A Report from Clinical breast cancer Registry of Iran.
Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A
Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847
[TBL] [Abstract] [Full Text] [Related]
6. Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in her2-positive and her2-negative breast cancer patients.
Thonusin C; Osataphan N; Leemasawat K; Nawara W; Sriwichaiin S; Supakham S; Gunaparn S; Apaijai N; Somwangprasert A; Phrommintikul A; Chattipakorn SC; Chattipakorn N
J Transl Med; 2024 Apr; 22(1):398. PubMed ID: 38685030
[TBL] [Abstract] [Full Text] [Related]
7. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
8. [Evaluation of PD-L1 expression and intratumoral lymphocytic infiltration in triple-negative invasive breast carcinoma].
Barrios Barreto R; Silvera Redondo C; Garavito MDP; Ardila Pereira L
Medicina (B Aires); 2024; 84(2):227-235. PubMed ID: 38683507
[TBL] [Abstract] [Full Text] [Related]
9. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract] [Full Text] [Related]
10. Interleukin (IL)-21 and IL-21 receptor expression in peripheral T and B cells of patients with breast cancer.
Babaeinia E; Ghods A; Rasolmali R; Talei AR; Mehdipour F; Ghaderi A
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):15-22. PubMed ID: 38678632
[TBL] [Abstract] [Full Text] [Related]
11. [Quantitative her2 mRNA assay in breast cancer with her2 immunohistochemistry 0].
Sun MC; Wu SF; Cai YM; Liu YY; Li KM; Zhao DC; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):464-469. PubMed ID: 38678327
[No Abstract] [Full Text] [Related]
12. The Impact of Neoadjuvant Chemotherapy on Axillary Surgical Management of Patients With breast cancer and Positive Axillary Lymph Nodes.
Cipolla C; Lupo S; Grassi N; Battaglia MC; Mesi C; Scandurra G; Gebbia V; Valerio MR
Anticancer Res; 2024 May; 44(5):2047-2053. PubMed ID: 38677748
[TBL] [Abstract] [Full Text] [Related]
13. Inactivation of the Tumor Suppressor CYLD Sensitizes Mice to breast cancer Development.
Pseftogas A; Xanthopoulos K; Siasiaridis A; Poutahidis T; Gonidas C; Tsingotjidou A; Hatzivassiliou E; Mosialos G
Anticancer Res; 2024 May; 44(5):1885-1894. PubMed ID: 38677721
[TBL] [Abstract] [Full Text] [Related]
14. breast cancer in Patients with Previous Endometriosis Showed Low Aggressive Subtype.
Vanni G; Selntigia A; Marsella VE; Russo C; Pellicciaro M; Materazzo M; Rizzo G; Buonomo OC; Exacoustos C
Medicina (Kaunas); 2024 Apr; 60(4):. PubMed ID: 38674271
[No Abstract] [Full Text] [Related]
15. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B breast cancer: A Pilot Study.
Camargo-Herrera V; Castellanos G; Rangel N; Jiménez-Tobón GA; Martínez-Agüero M; Rondón-Lagos M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674062
[TBL] [Abstract] [Full Text] [Related]
16. Analysis on status quo and related factors of delays in diagnosis and treatment of breast cancer in Ningxia Hui Autonomous Region.
Wang Y; Bai Z; Liu Q; Yu H; Tang Z; Liu X; Liu Q
Medicine (Baltimore); 2024 Apr; 103(17):e37826. PubMed ID: 38669416
[TBL] [Abstract] [Full Text] [Related]
17. Impact of Pregnancy on breast cancer Features and Prognosis.
Bounous VE; Minella C; Fuso L; Actis S; Petroni G; Sgrò LG; Borghese M; Tomasi Cont N; Ponzone R; Ferrero A
Curr Oncol; 2024 Apr; 31(4):2305-2315. PubMed ID: 38668074
[TBL] [Abstract] [Full Text] [Related]
18. Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic breast cancer in a Canadian Setting Using AI-Extracted Data.
Moulson R; Feugère G; Moreira-Lucas TS; Dequen F; Weiss J; Smith J; Brezden-Masley C
Curr Oncol; 2024 Apr; 31(4):2172-2184. PubMed ID: 38668064
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
[TBL] [Abstract] [Full Text] [Related]
20. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated her2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract] [Full Text] [Related]
[Next]
